Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study

Daniel J Smith, Julie Langan, Gary McLean, Bruce Guthrie, Stewart W Mercer

ABSTRACT

Objective: To assess the nature and extent of physical-health comorbidities in people with schizophrenia and related psychoses compared with controls.

Design: Cross-sectional study.

Setting: 314 primary care practices in Scotland.

Participants: 9677 people with a primary care record of schizophrenia or a related psychosis and 1 414 701 controls. Main outcome measures Primary care records of 32 common chronic physical-health conditions and combinations of one, two and three or more physical-health comorbidities adjusted for age, gender and deprivation status.

Results: Compared with controls, people with schizophrenia were significantly more likely to have one physical-health comorbidity (OR 1.21, 95% CI 1.16 to 1.27), two physical-health comorbidities (OR 1.37, 95% CI 1.29 to 1.44) and three or more physical-health comorbidities (OR 1.19, 95% CI 1.12 to 1.27). Rates were highest for viral hepatitis (OR 3.98, 95% CI 2.81 to 5.64), constipation (OR 3.24, 95% CI 3.00 to 4.49) and Parkinson’s disease (OR 3.07, 95% CI 2.42 to 3.88) but people with schizophrenia had lower recorded rates of cardiovascular disease, including atrial fibrillation (OR 0.62, 95% CI 0.51 to 0.73), hypertension (OR 0.71, 95% CI 0.67 to 0.76), coronary heart disease (OR 0.75, 95% CI 0.61 to 0.71) and peripheral vascular disease (OR 0.83, 95% CI 0.71 to 0.97).

Conclusions: People with schizophrenia have a wide range of comorbid and multiple physical-health conditions but are less likely than people without schizophrenia to have a primary care record of cardiovascular disease. This suggests a systematic under-recognition and undertreatment of cardiovascular disease in people with schizophrenia, which might contribute to substantial premature mortality observed within this patient group.

ARTICLE SUMMARY

Article focus

- People with a diagnosis of schizophrenia are known to be at high risk of poor physical-health outcomes and premature mortality due to cardiovascular disease, diabetes, obesity and smoking-related lung disease.
- The nature and extent of multiple physical-health comorbidities within this patient group are poorly understood.
- In a large primary care dataset of almost 1.8 million individuals, we assessed how patterns of multiple physical-health comorbidities in schizophrenia are influenced by age, gender and social deprivation.

Key messages

- People with schizophrenia have a wide range of multiple-comorbid physical-health problems compared with people without schizophrenia, even after controlling for the effects of age, gender and social deprivation.
- Recorded rates were highest for viral hepatitis, constipation and Parkinson’s disease but were lower than expected for a number of cardiovascular disorders, including atrial fibrillation, hypertension, coronary heart disease and peripheral vascular disease.
- This suggests a systematic under-recognition and undertreatment of cardiovascular disease of people with schizophrenia within primary care, which might contribute to the substantial cardiovascular-related morbidity and premature mortality observed in this patient group.

INTRODUCTION

Individuals with chronic-mental disorders such as schizophrenia have increased standardised death rates compared with the general population. On average, men with schizophrenia die 20 years earlier and women die 15 years earlier than people without major mental illness. Although death due to suicide is a contributing factor, approximately two-thirds of this premature
mortality are attributable to cardiovascular disease, smoking-related lung disease and type II diabetes. Rates of smoking in schizophrenia are estimated at 70% compared with 20% in the general population, and at least 10% of patients prescribed long-term antipsychotic medications will develop type II diabetes, more than twice the rate in the general population. There may also be a shared genetic vulnerability between psychosis and risk of diabetes.

To date, there have been very few large-scale representative studies from primary care which assess the nature and extent of physical-health comorbidity in people with schizophrenia, as well as the influence of age, gender and socioeconomic deprivation. Here, we examine the range and number of the most common physical-health comorbidities within a sample of 9677 people with a recorded diagnosis of schizophrenia or a related psychosis, identified from a large Scottish primary care database of almost 1.8 million individuals.

METHODS
We used a dataset from the Primary Care Clinical Informatics Unit at the University of Aberdeen which consists of all 1,751,841 registered patients who were alive and permanently registered with 314 general practices on 31 March 2007. This sample represents approximately one-third of the Scottish population. Data on the presence of 32 of the most common chronic physical-health conditions were extracted (listed in table A1). A more detailed explanation on how these conditions were selected and defined is available elsewhere.

People were identified as having ‘schizophrenia or related non-organic psychosis’ (hereafter referred to as ‘schizophrenia’) based on the recording ever of any of the following primary care read codes (where % is noted, this means ‘this code and any below it in the code hierarchy’): E10% schizophrenic disorders; E121 chronic paranoid psychosis; E12z paranoid psychosis NOS; E13% other non-organic psychoses; E13z non-organic psychosis/psychotic episode; NOS E12 non-organic psychosis NOS; Eu20% schizophrenia; Eu22% persistent delusional disorder or the recording in the last 12 months of Eu23% acute/transient psychotic disorder. We restricted our analyses of this dataset to individuals aged 18 and over and the sample was divided into the following age groups for analysis: 18–24; 25–34; 35–44; 45–54; 55–64; 65–75 and 75 and over. Eight individuals with schizophrenia who were under age 18 were excluded. Deprivation status was measured using the Carstairs deprivation score which is widely used in health research (divided into quintiles).

Differences between those with schizophrenia (cases), all other individuals (controls) and between female and male individuals with schizophrenia were calculated by age, deprivation and number of physical conditions. We used tests to analyse differences between groups and one-way analysis of variance for differences across age groups and deprivation quintiles. Logistic regression was used to calculate ORs and 95% CIs in those with schizophrenia compared with controls for the prevalence of all 32 physical conditions, as well as no physical disorder, one comorbid disorder and two or more comorbid disorders. OR calculations were adjusted for age, gender and deprivation score. All analyses were performed in Stata V.11. The NHS National Research Ethics Service approved the anonymous use of these data for research purposes.

RESULTS
Age, gender and deprivation status, schizophrenia versus controls
We identified 9677 people with schizophrenia (0.7% of the entire sample) and 1,414,701 controls (table 1). Those with schizophrenia were more likely to be male (schizophrenia 51.5% men vs controls 49.1% men; p<0.001) and tended to be older than controls (schizophrenia mean age 51.6 years vs controls mean age 48 years; p<0.001), although the magnitude of these differences was small. Individuals with schizophrenia were more socially deprived on average (schizophrenia Carstairs score 0.34 vs controls −0.17; p<0.001), with 23.3% living in the most deprived quintile of postcodes versus 17.8% of controls.

Physical-health comorbidity in people with schizophrenia versus controls
Physical-health comorbidities were very common in people with schizophrenia, even after adjusting for age, gender and deprivation score. Compared with individuals without schizophrenia, they were significantly less likely to have no recorded comorbidity (OR 0.61, 95% CI 0.58 to 0.64) and significantly more likely to have one comorbidity (OR 1.21, 95% CI 1.16 to 1.27), two comorbidities (OR 1.37, 95% CI 1.29 to 1.44) and three or more comorbidities (OR 1.19, 95% CI 1.12 to 1.27; table 2).

For each of the 32 individual physical conditions assessed, prevalence was significantly higher for people with schizophrenia for 16 conditions, lower for 6 conditions and with no difference for the remaining 10 conditions (table 2 and figure 1). Prevalence was highest for schizophrenia versus controls for viral hepatitis (OR 3.98, 95% CI 2.81 to 5.64), constipation (OR 3.24, 95% CI 3.00 to 4.49) and Parkinson’s disease (OR 3.07, 95% CI 2.42 to 3.88). People with schizophrenia also had
higher rates of several important chronic health conditions, including diabetes (9% in schizophrenia vs 5.2% in controls; p<0.001), chronic obstructive pulmonary disease (COPD; 6% vs 3.1%; p<0.001) and chronic pain (13.8% vs 8.8%; p<0.001).

The most commonly diagnosed condition for individuals with schizophrenia was hypertension (16%), although this rate was lower than in controls (16.5%). It is also noteworthy that for the six conditions in which the relative prevalence for schizophrenia patients was lower, four were cardiovascular-related, including atrial fibrillation (OR 0.62, 95% CI 0.51 to 0.73), hypertension (OR 0.71, 95% CI 0.67 to 0.76), coronary heart disease (OR 0.75, 95% CI 0.61 to 0.71) and peripheral vascular disease (OR 0.83, 95% CI 0.71 to 0.97).

Gender differences within the schizophrenia group
We assessed whether there might be differences between men and women with schizophrenia in terms of the number of recorded physical-health comorbidities, as well as age and deprivation status (Table 3). Physical comorbidity was high in all schizophrenia patients, with two-thirds of women and 50% of men having at least one recorded comorbid physical condition (Table 2). Women with schizophrenia were significantly more likely to have two or more physical conditions (18.1% vs 12.9%; p<0.001) and three or more physical conditions (23.9% vs 12.6%; p<0.001).

Discussion
In keeping with several recent reports, this study highlights that multiple physical-health comorbidity is a major issue for people with schizophrenia and related psychoses. A majority of people with schizophrenia had at least one chronic physical comorbidity and one-third had two or more. Compared with patients without schizophrenia, patients with schizophrenia were much more likely to have a primary care record of both single and multiple physical-health problems, even after taking into account age, gender and deprivation status. We found three conditions to be particularly over-represented in the schizophrenia group (viral hepatitis, constipation and Parkinson’s disease), as well as high rates of diabetes, chronic pain, epilepsy, COPD, dyspepsia, liver disease and irritable bowel syndrome.

Under-recording of cardiovascular disease
Perhaps the most notable finding in this study was that individuals with schizophrenia and related psychoses had significantly lower recorded rates of cardiovascular disorders (including atrial fibrillation, hypertension, congestive heart disease and peripheral vascular disease) than individuals without schizophrenia. This finding is somewhat unexpected, given that several previous studies have found high rates of cardiovascular morbidity and mortality in schizophrenia. However, a population-based study of administrative claims data in the USA has found that rates of hypertension and ischaemic heart disease were lower than expected in individuals with schizophrenia compared with controls. Similarly, a recent meta-analysis of prescribing data for patients with and without major mental illness (including schizophrenia) found that those with severe mental illness had much lower than expected rates of being prescribed medications for cardiovascular disease. In a recent Swedish national cohort study, people with incident schizophrenia were more likely to die prematurely than the general population (15 years earlier for men...
and 12 years earlier for women) and the leading causes of death were cardiovascular disease and cancer. However, in this study, the rates of recording of cardiovascular disease and cancer were not much increased in people with schizophrenia, even though these individuals had more healthcare system contacts, suggesting that cardiovascular disease and cancer are significantly under-diagnosed and/or under-recorded in this population.4

There may be several possible explanations for our findings. People with schizophrenia may be less likely to consult their general practitioner (GP) with symptoms of cardiac or vascular disease because of low awareness of cardiovascular risk and associated symptoms,17 or they may be more likely to not have these areas investigated, diagnosed18 and monitored.19 They might also expect that their physical health needs are being met by their community mental health teams.4 In general, rates of consultation in individuals with major mental illness are comparable to the general population20 but it is possible that relatively asymptomatic conditions such as atrial fibrillation are less likely to be identified than constipation, irritable bowel syndrome, Parkinson’s disease, dyspepsia and epilepsy. It is also possible that, even when these patients do attend, GPs may not be assessing and/or recording cardiac problems as often as they might with patients who do not have schizophrenia.18 It is well documented that patients with mental illness and comorbid physical problems do not receive the same level of assessment and treatment for their physical problems as patients without mental illness.21 22

Hypertension was the most common comorbidity recorded within the schizophrenia group but was

| Table 2  | Prevalence and adjusted ORs for physical-health comorbidity (adjusted for age, gender and deprivation score) |
|----------|--------------------------------------------------------------------------------------------------|
|          | Schizophrenia number (%) | Controls number (%) | OR (95% CI)                      |
| No physical comorbidity | 4069 (42.1) | 796039 (56.3) | 0.61 (0.58 to 0.64) (p<0.001) |
| One physical comorbidity | 2363 (24.4) | 290950 (20.6) | 1.21 (1.16 to 1.27) (p<0.001) |
| Two physical comorbidities | 1493 (15.4) | 148231 (10.5) | 1.37 (1.29 to 1.44) (p<0.001) |
| Three or more physical comorbidities | 1752 (18.1) | 179481 (12.7) | 1.19 (1.12 to 1.27) (p<0.001) |

| Individual conditions | Schizophrenia number (%) | Controls number (%) | OR (95% CI)                      |
|-----------------------|--------------------------|---------------------|---------------------------------|
| Viral hepatitis       | 33 (0.3)                 | 1142 (0.1)          | 3.98 (2.81 to 5.64) (p<0.001)   |
| Constipation          | 873 (9.0)                | 35543 (2.5)         | 3.24 (3.00 to 3.49) (p<0.001)   |
| Parkinson’s disease   | 73 (0.8)                 | 2668 (0.2)          | 3.07 (2.42 to 3.88) (p<0.001)   |
| Epilepsy              | 213 (2.2)                | 12171 (0.9)         | 2.42 (2.11 to 2.77) (p<0.001)   |
| Dyspepsia             | 1106 (11.4)              | 78098 (5.5)         | 1.92 (1.80 to 2.05) (p<0.001)   |
| Liver disease         | 36 (0.4)                 | 2578 (0.2)          | 1.66 (1.19 to 2.31) (p<0.001)   |
| Irritable bowel syndrome (IBS) | 540 (5.6) | 51597 (3.7) | 1.57 (1.44 to 1.72) (p<0.001)   |
| Diabetes              | 870 (9.0)                | 73961 (5.2)         | 1.52 (1.40 to 1.64) (p<0.001)   |
| Blindness             | 104 (1.1)                | 8274 (0.6)          | 1.44 (1.18 to 1.75) (p<0.001)   |
| Thyroid disorders     | 738 (7.6)                | 71205 (5.0)         | 1.43 (1.32 to 1.54) (p<0.001)   |
| Pain                  | 1332 (13.8)              | 124799 (8.8)        | 1.39 (1.30 to 1.47) (p<0.001)   |
| Psoriasis and eczema  | 101 (1.0)                | 10268 (0.7)         | 1.34 (1.10 to 1.63) (p<0.001)   |
| Chronic obstructive pulmonary disease (COPD) | 577 (6.0) | 52530 (3.1) | 1.31 (1.20 to 1.43) (p<0.001)   |
| Migraine              | 79 (0.8)                 | 9172 (0.7)          | 1.27 (1.02 to 1.59) (p=0.03)    |
| Asthma                | 696 (7.2)                | 83809 (5.9)         | 1.22 (1.12 to 1.31) (p<0.001)   |
| Heart failure         | 167 (2.0)                | 18703 (1.3)         | 1.15 (0.99 to 1.32) (p=0.06)    |
| Hearing loss          | 495 (5.1)                | 54239 (3.8)         | 1.14 (1.04 to 1.25) (p<0.001)   |
| Sinusitis             | 69 (0.7)                 | 9096 (0.6)          | 1.10 (0.86 to 1.34) (p=0.42)    |
| Stroke and TIA        | 350 (3.6)                | 36195 (2.6)         | 1.07 (0.96 to 1.20) (p=0.19)    |
| Crohn’s disease       | 71 (0.7)                 | 9680 (0.7)          | 1.03 (0.81 to 1.33) (p=0.80)    |
| Bronchiectasis        | 23 (0.2)                 | 2791 (0.2)          | 0.99 (0.66 to 1.50) (p=0.99)    |
| Diverticular disease  | 283 (2.9)                | 33530 (2.4)         | 0.96 (0.84 to 1.09) (p=0.61)    |
| Chronic kidney disease | 291 (3.0)              | 33275 (2.4)         | 0.95 (0.84 to 1.08) (p=0.48)    |
| Glaucoma              | 123 (1.3)                | 15796 (1.2)         | 0.88 (0.73 to 1.04) (p=0.15)    |
| Multiple sclerosis    | 23 (0.3)                 | 3824 (0.3)          | 0.88 (0.59 to 1.33) (p=0.56)    |
| Prostate disease      | 114 (1.2)                | 15119 (1.1)         | 0.86 (0.71 to 1.03) (p=0.11)    |
| Peripheral vascular disease | 167 (1.7) | 23073 (1.6) | 0.83 (0.71 to 0.97) (p=0.02)    |
| Inflammatory arthritis | 389 (4.0)               | 57619 (4.1)         | 0.82 (0.74 to 0.91) (p<0.001)   |
| Cancer                | 288 (3.0)                | 43376 (3.1)         | 0.81 (0.72 to 0.91) (p<0.001)   |
| Coronary heart disease | 579 (5.9)               | 80888 (5.7)         | 0.75 (0.69 to 0.82) (p<0.001)   |
| Hypertension          | 1551 (16.0)              | 232763 (16.5)       | 0.71 (0.67 to 0.76) (p<0.001)   |
| Atrial fibrillation   | 137 (1.4)                | 23839 (1.7)         | 0.62 (0.51 to 0.73) (p<0.001)   |

TIA, transient ischaemic attack.
significantly less common than in the control group (OR 0.71, 95% CI 0.67 to 0.76). It is possible that this could be due to the use of antihypertensive agents for symptoms such as anxiety or akathisia in the schizophrenia group or the hypotensive effect of some antipsychotic medications, but the most likely explanation in our view would be less frequent monitoring of blood pressure in primary care for patients with schizophrenia relative to controls. Having said this, a recent systematic review of features of metabolic syndrome in schizophrenia and related disorders found increased rates of hypertension, so this is an area in need of more research.23

Although it will be important for our findings to be replicated, this and other studies are consistent with a systematic underdiagnosis of cardiovascular disease in patients with schizophrenia, which, coupled with the undertreatment of the diagnosed disease, may contribute to the high rates of cardiovascular morbidity and premature mortality observed in this patient group.

Other medical comorbidities

Although difficult to clarify within this dataset, it is possible to speculate on the reasons for the high rates of viral hepatitis, constipation and Parkinson’s disease

### Table 3 Differences between women and men with schizophrenia

| Variable                  | Women Number (%) | Men Number (%) | Difference 95% CI (p<0.001) |
|---------------------------|------------------|----------------|-------------------------------|
| Total                     | 4716 (48.7)      | 4961 (51.3)    | 7.8 (7.2 to 8.4)              |
| Age mean (SD)             | 55.6 (17.0)      | 47.8 (15.2)    | −1.8 (−1.1 to −2.4)           |
| Deprivation mean (SD)     | 0.29 (3.4)       | 0.77 (3.5)     | −0.5 (−0.34 to −0.68)         |
| Age group (years)         |                  |                |                               |
| 18–24                     | 102 (2.2)        | 196 (4.0)      | −1.8 (−1.1 to −2.4)           |
| 25–34                     | 400 (8.5)        | 816 (16.5)     | −8.0 (6.7 to 9.2)             |
| 35–44                     | 865 (18.3)       | 1275 (25.7)    | −7.4 (−5.7 to −9.0)           |
| 45–54                     | 968 (20.5)       | 1111 (22.4)    | −1.9 (−0.2 to −3.5)           |
| 55–64                     | 935 (19.8)       | 836 (16.9)     | 2.9 (1.4 to 4.5)              |
| 65–74                     | 663 (14.1)       | 431 (8.7)      | 5.4 (4.1 to 6.6)              |
| 75 and over               | 783 (16.6)       | 296 (6.0)      | 10.6 (9.9 to 11.3)            |
| Deprivation quintile      |                  |                |                               |
| 1—Least deprived          | 678 (14.4)       | 582 (11.7)     | 2.6 (1.3 to 3.9)              |
| 2                         | 862 (18.3)       | 852 (17.2)     | 1.1 (−0.4 to 2.0)             |
| 3                         | 1146 (24.3)      | 1117 (22.5)    | 1.8 (0.0 to 3.4)              |
| 4                         | 1060 (22.5)      | 1130 (22.8)    | −0.3 (−1.9 to 0.3)            |
| 5—Most deprived           | 970 (20.6)       | 1280 (25.8)    | −5.2 (−3.6 to −6.9)           |
| Number of comorbidities   |                  |                |                               |
| No physical               | 1577 (33.4)      | 2492 (50.2)    | −16.8 (−14.9 to 3.9)          |
| One physical              | 1155 (24.5)      | 1208 (24.4)    | 0.1 (−1.5 to 1.8)             |
| Two physical              | 855 (18.1)       | 638 (12.9)     | 5.2 (3.8 to 6.7)              |
| Three or more             | 1129 (23.9)      | 623 (12.6)     | 11.3 (9.8 to 12.9)            |
within the schizophrenia group. For example, this sample (which comprised ‘schizophrenia and related psychoses’) is likely to include a proportion of people with a history of drug misuse who will be at higher risk of viral hepatitis. It is possible that this has contributed to the higher recorded rates of viral hepatitis within the schizophrenia group.

Constipation is an important though often neglected side effect of antipsychotic medication,24 25 and it is of interest that it was much more commonly recorded in the schizophrenia group than in controls. However, most estimates suggest that between 20% and 30% of all patients taking antipsychotic medications will have constipation.25 The prevalence of 9% within the schizophrenia group in our study is therefore likely to be an underestimate of the true figure.

Although relatively rarely recorded, Parkinson’s disease was significantly more common in the schizophrenia group than in controls (0.8% vs 0.2%, OR 3.07, 95% CI 2.42 to 3.88) and could also represent a common extrapyramidal side effect of antipsychotic medication.

Gender differences

We found that patients with schizophrenia (and particularly men) were over-represented in areas of higher social deprivation. It is well documented that socio-economic disadvantage and urban residence contribute to the risk of developing a psychotic disorder,26 but the cross-sectional nature of our data make it difficult to assess whether our finding is due to this or is a consequence of social drift. Additionally, we found that women with schizophrenia were more likely than men with schizophrenia to have multiple comorbidities—this gender difference was also observed in the Swedish national cohort study noted above.4 In our dataset, it might be explained by the fact that women with schizophrenia were older on average than men with schizophrenia (possibly due to the greater prematurity mortality for men) and the possibility that women are more likely to consult with their GP than men.27 Future work should seek to explore these gender differences in more detail, for example, by assessing the help-seeking behaviours of men and women with schizophrenia and how these behaviours are influenced by age and socio-economic background.

Strengths and limitations

The strengths of this study include the large sample size (almost 1.8 million individuals), which is representative of the Scottish population, but some potential limitations should be noted. The rate of a recorded diagnosis of schizophrenia or a related psychotic disorder of 0.7% could be considered to be lower than expected, with most estimates of the prevalence of schizophrenia around 1%,28 although it is recognised that estimates of the incidence and prevalence of schizophrenia can be subject to wide variations across different locations because of the differences in population characteristics, exposure levels and diagnostic assessment.28 It is possible that some patients with schizophrenia or a related psychotic disorder are known to secondary care services but are not recorded within primary care and that a small additional proportion may not be in contact with either primary or secondary care. Further, these are routine data from 314 primary care practices and there may be some variability of diagnostic coding for major mental illnesses across these practices. Conversely, it is possible that in addition to the under-recognition and under-recording of cardiovascular disease in patients with schizophrenia, some of the prevalence rates for other physical-health comorbidities may be underestimated.

Conclusions

Overall, this study highlights that people with schizophrenia have high rates of multiple comorbid physical health problems, emphasising the importance of an integrated approach to their care.29 30 It is well documented that physical and mental health problems interact to cause prolonged hospitalisation, treatment failure, poor quality of life and premature mortality.15 16 31 The current separation between specialist physical and mental health services, and between primary and secondary care services in the UK and other countries, makes the co-ordinated care of the physical health of patients with schizophrenia difficult. Several recent reports have highlighted that more integrated services are needed but how best to achieve this is currently unclear.32–34 This issue may be particularly relevant for cardiac disease because, although many studies have found that patients with schizophrenia have high rates of cardiovascular morbidity and mortality, our findings and other recent evidence suggest that they have lower than expected rates of being diagnosed with and treated for cardiovascular disorders.

Integrated care requires the delivery of preventive and curative health services which vary according to individual needs over time and across different levels of the healthcare system and can be difficult to achieve. Given that cardiovascular risk assessment has been shown to be acceptable to many people with psychosis,35 a more systematic use of such screening in both primary and secondary care may improve early detection and treatment of hypertension, hypercholesterolaemia, diabetes and smoking. Further research is needed to evaluate the effectiveness of such approaches to improve the physical health and life expectancy of people with schizophrenia.

Acknowledgements

We thank Katie Wilde and Fiona Chaloner of the University of Aberdeen, who did the initial data extraction and management.

Contributors

DJ, JL, BG and SWM conceived the idea of the study, GML carried out statistical analyses, DJJS wrote the first draft and all authors contributed to revisions of this draft. All authors approved the final version before submission. SWM is the guarantor for this study.

Funding

We thank the Chief Scientist Office of the Scottish Government Health Directorates (Applied Research Programme Grant ARPG/07/1); the Scottish School of Primary Care, which part-supported SWM’s post and the
development of the Applied Research Programme; and the Primary Care Clinical Informatics Unit at the University of Aberdeen, which provided the data. The views in this publication are not necessarily the views of the University of Aberdeen or University of Glasgow, their agents or employees.

Competing interests In the last 5 years, DJS has received fees for speaking at educational meetings arranged by Lundbeck, AstraZeneca and Eli Lilly and BMS and consultancy fees from Lundbeck.

Ethics approval NHS National Research Ethics Service.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

REFERENCES

1. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ 2011;343:d5422.

2. Wahlbeck K, Wilhelm J, Nordenfelt M, et al. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. Br J Psychiatry 2011;199:453–8.

3. Laursen TM, Munk-Olsen T, Gasses C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS ONE 2011;6:e24597.

4. Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013;170:324–33.

5. Tihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620–27.

6. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:899–16.

7. Laursen TM, Munk-Olsen T, Nordenfelt M, et al. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder and schizophrenia. J Clin Psychiatry 2007;68:899–907.

8. Heilla H, Haukka J, Susvisaari J, et al. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 2005;35:725–32.

9. Myles N, Newall HD, Curtis J. Tobacco use before, at and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry 2012;73:468–75.

10. Akhtar S, Kelly C, Gallagher A, et al. Review: newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk. Br J Diabetes Vasc Dis 2004;4:303–9.

11. Ole A Andreassen, Djurovic S, Wesley K Thompson, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 2013;92:197–209.

12. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37–43.

13. Carstairs V, Morris R. Deprivation and health in Scotland: Aberdeen: Edinburgh University Press, 1991.

14. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia. A population-based controlled study. J Gen Intern Med 2006;21:1133–7.

15. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52–77.
### Table A1 Definitions of 32 physical-health conditions assessed

| Condition                                      | Variable name | Variable definition                                                                 |
|------------------------------------------------|---------------|--------------------------------------------------------------------------------------|
| Coronary heart disease                        | CHD           | Read code ever recorded                                                              |
| Chronic kidney disease                        | CKD           | Read code ever recorded                                                              |
| Asthma (active)                               | Asthma        | Read code ever recorded AND any prescription in the previous year                    |
| Atrial fibrillation                           | Atrial fibrillation | Read code ever recorded                                                                 |
| Epilepsy                                      | Epilepsy      | Read code ever recorded AND epilepsy prescription in the previous year                |
| New cancer in the last 5 years                | Cancer        | Read code first recorded in the last 5 years (Relevant Read Code recorded)           |
| Thyrotoxicosis/thyroid disorders (includes hypothyroidism) | Thyroid disorders | Read code ever recorded (Relevant Read Code recorded)                                  |
| Diabetes                                      | Diabetes      | Read code ever recorded                                                              |
| Parkinson’s disease                           | Parkinson’s disease | Read code ever recorded (Relevant Read Code recorded)                                |
| Multiple sclerosis                            | Multiple sclerosis | Read code ever recorded (Relevant Read Code recorded)                                 |
| Stroke or transient ischaemic attack          | Stroke or TIA | Read code ever recorded (Relevant Read Code recorded)                                 |
| Blindness and low vision                      | Blindness     | Read code ever recorded (Relevant Read Code recorded)                                 |
| Glaucoma                                      | Glaucoma      | Read code ever recorded (Relevant Read Code recorded)                                 |
| Hearing loss                                  | Hearing loss  | Read code ever recorded (Relevant Read Code recorded)                                 |
| Hypertension                                  | Hypertension  | Read code ever recorded (Relevant Read Code recorded)                                 |
| Heart failure                                 | Heart failure | Read code ever recorded                                                              |
| Peripheral vascular diseases                  | PVD           | Read code ever recorded (Relevant Read Code recorded)                                 |
| Chronic sinusitis                             | Sinusitis     | Read code ever recorded (Relevant Read Code recorded)                                 |
| Bronchitis, emphysema & other chronic obstructive pulmonary diseases | COPD | Read code ever recorded (Relevant Read Code recorded)                                 |
| Bronchiectasis                                | Bronchiectasis | Read code ever recorded (Relevant Read Code recorded)                                |
| Crohn’s disease and ulcerative colitis        | Inflammatory bowel disease | Read code ever recorded (Relevant Read Code recorded)                                |
| Diverticular disease of the intestine         | Diverticular disease | Read code ever recorded (Relevant Read Code recorded)                                |
| Rheumatoid arthritis, other inflammatory polyarthropathies and systematic connective tissue disorders | Inflammatory arthritis | Read code ever recorded (Relevant Read Code recorded)                                 |
| Hyperplasia of prostate and prostate disorders | Prostate disease | Read code ever recorded (Relevant Read Code recorded)                                 |
| Psoriasis or eczema                           | Psoriasis/eczema | Read code ever recorded (M11% & M12%) AND ≥ 4 prescription in last year (BNF 13.4, excluding hydrocortisone and BNF 13.5) |
| Viral hepatitis                               | Viral hepatitis | Read code ever recorded (Relevant Read Code recorded)                                 |
| Irritable bowel syndrome                      | Irritable bowel syndrome | Read code ever recorded (Relevant Read Code recorded) OR ≥ 4 antispasmodic prescription in the previous year (POM only, exclude kolanticon, alverine citrate and peppermint oil) |

Continued
| Condition                                      | Variable name | Variable definition                                                                 |
|------------------------------------------------|---------------|--------------------------------------------------------------------------------------|
| Cirrhosis/chronic liver disease/alcoholic liver | Chronic liver | Read code ever recorded (Relevant Read Code recorded)                                 |
| disease                                        | disease       | ≥4 anti-migraine prescriptions in last year (BNF 040704%, POM only exclude migraleve) |
| Migraine                                       | Migraine      | ≥4 prescriptions in last year BNF 0103% excluding antacids AND NOT ≥4 NSAIDS OR ≥4 aspirin/ |
|                                                |               | clopidogrel                                                                         |
| Dyspepsia                                      | Dyspepsia     | ≥4 prescriptions in last year, BNF 0106%                                            |
| Constipation pain                              | Constipation  | ≥4 specified analgesic prescriptions in the previous year (opioids/>8 mg cocodamol/NSAIDS) OR ≥4 |
| pain                                           | pain          | specified antiepileptics in the absence of an epilepsy Read code in last year (gabapentin, pregbalin and carbamazpine) |

BNF, British National Formulary; NSAIDS, non-steroidal anti-inflammatory drugs; POM, prescription only medicine.